Traditional Chinese Medicine as the Preventive and Therapeutic Remedy for COVID-19


Cite item

Full Text

Abstract

The coronavirus disease 2019 (COVID-19) pandemic still has tremendous impacts on the global socio-economy and quality of living. The traditional Chinese Medicines (TCM) approach showed encouraging results during previous outbreaks of Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). With limited treatment availability, TCM herbs and formulations could be useful to reduce COVID-19 symptoms and potential sources for discovering novel therapeutic targets. We reviewed 12 TCM herbs and formulations recommended for COVID-19 management by the National Health Commission and as National Administration of Traditional Chinese Medicine of the People's Republic of China. This article explored the Chinese national authorities' guidelines from 2003 to 2020, the scientific data in public databases for the recommended TCM remedies, and their potential mechanistic actions in COVID-19 management. Several TCM herbs and formulations could potentially benefit COVID-19 management. The recommended TCM oral preparations list includes Huoxiang zhengqi, Jinhua Qinggan, Lianhua Qingwen, and Shufeng jiedu; the recommended injection preparations comprise Xiyanping Xuebijing, Re-Du-Ning, Tanreqing, Xingnaojing, Shenfu, Shengmai, and Shenmai. TCM remedies are viable options for symptom alleviation and management of COVID-19. The current SARS-CoV-2 pandemic presents an opportunity to find novel therapeutic targets from TCM-active ingredients. Despite the recommendations in Chinese National guidelines, these remedies warrant further assessments in well-designed clinical trials to ascertain their efficacy in the treatment of COVID-19.

About the authors

Amin Gasmi

, Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée

Email: info@benthamscience.net

Torsak Tippairote

Nutritional and Environmental Section, Thailand Initiatives for Functional Medicine

Email: info@benthamscience.net

Pavan Mujawdiya

, Birla Institute of Technology and Science-Pilani

Email: info@benthamscience.net

Alain Menzel

, Laboratoires Réunis

Email: info@benthamscience.net

Roman Lysiuk

Department of Pharmacognosy and Botany, Danylo Halytsky Lviv National Medical University

Email: info@benthamscience.net

Mariia Shanaida

Department of Pharmacognosy and Medical Botany, I. Horbachevsky Ternopil National Medical University

Email: info@benthamscience.net

Larysa Lenchyk

Department of Quality, Standardization and Certification of Medicines of IATPS, National University of Pharmacy

Email: info@benthamscience.net

Massimiliano Peana

Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari

Email: info@benthamscience.net

Geir Bjørklund

, Council for Nutritional and Environmental Medicine

Author for correspondence.
Email: info@benthamscience.net

References

  1. Yang, Y.; Peng, F.; Wang, R.; Guan, K.; Jiang, T.; Xu, G.; Sun, J.; Chang, C.; Chang, C. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun., 2020, 109, 102434. doi: 10.1016/j.jaut.2020.102434 PMID: 32143990
  2. Zhang, D.; Wu, K.; Zhang, X.; Deng, S.; Peng, B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J. Integr. Med., 2020, 18(2), 152-158. doi: 10.1016/j.joim.2020.02.005 PMID: 32113846
  3. Totura, A.L.; Bavari, S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin. Drug Discov., 2019, 14(4), 397-412. doi: 10.1080/17460441.2019.1581171 PMID: 30849247
  4. Gasmi, A.; Peana, M.; Pivina, L.; Srinath, S.; Gasmi Benahmed, A.; Semenova, Y.; Menzel, A.; Dadar, M.; Bjørklund, G. Interrelations between COVID-19 and other disorders. Clin. Immunol., 2021, 224, 108651. doi: 10.1016/j.clim.2020.108651 PMID: 33333255
  5. Araf, Y.; Akter, F.; Tang, Y.; Fatemi, R.; Parvez, M.S.A.; Zheng, C.; Hossain, M.G. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J. Med. Virol., 2022, 94(5), 1825-1832. doi: 10.1002/jmv.27588 PMID: 35023191
  6. Hossain, M.K.; Hassanzadeganroudsari, M.; Apostolopoulos, V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Rev. Vaccines, 2021, 20(6), 635-638. doi: 10.1080/14760584.2021.1915140 PMID: 33896316
  7. Bakowski, M.A.; Beutler, N.; Wolff, K.C.; Kirkpatrick, M.G.; Chen, E.; Nguyen, T.T.H.; Riva, L.; Shaabani, N.; Parren, M.; Ricketts, J.; Gupta, A.K.; Pan, K.; Kuo, P.; Fuller, M.; Garcia, E.; Teijaro, J.R.; Yang, L.; Sahoo, D.; Chi, V.; Huang, E.; Vargas, N.; Roberts, A.J.; Das, S.; Ghosh, P.; Woods, A.K.; Joseph, S.B.; Hull, M.V.; Schultz, P.G.; Burton, D.R.; Chatterjee, A.K.; McNamara, C.W.; Rogers, T.F. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun., 2021, 12(1), 3309. doi: 10.1038/s41467-021-23328-0 PMID: 34083527
  8. Sultana, J.; Crisafulli, S.; Gabbay, F.; Lynn, E.; Shakir, S.; Trifirò, G. Challenges for drug repurposing in the COVID-19 pandemic era. Front. Pharmacol., 2020, 11, 588654. doi: 10.3389/fphar.2020.588654 PMID: 33240091
  9. Gasmi, A.; Peana, M.; Noor, S.; Lysiuk, R.; Menzel, A.; Gasmi Benahmed, A.; Bjørklund, G. Chloroquine and hydroxychloroquine in the treatment of COVID-19: The never-ending story. Appl. Microbiol. Biotechnol., 2021, 105(4), 1333-1343. doi: 10.1007/s00253-021-11094-4 PMID: 33515285
  10. Gong, W.J.; Zhou, T.; Wu, S.L.; Ye, J.L.; Xu, J.Q.; Zeng, F.; Su, Y.Y.; Han, Y.; Lv, Y.N.; Zhang, Y.; Cai, X.F. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. J. Infect. Chemother., 2021, 27(6), 876-881. doi: 10.1016/j.jiac.2021.02.018 PMID: 33676844
  11. Hassanipour, S.; Arab-Zozani, M.; Amani, B.; Heidarzad, F.; Fathalipour, M.; Martinez-de-Hoyo, R. Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep., 2022, 12(1), 1996. doi: 10.1038/s41598-022-05835-2 PMID: 35105913
  12. Hassanipour, S.; Arab-Zozani, M.; Amani, B.; Heidarzad, F.; Fathalipour, M.; Martinez-de-Hoyo, R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep., 2021, 11(1), 11022. doi: 10.1038/s41598-021-90551-6 PMID: 34040117
  13. Lai, C.C.; Chen, C.H.; Wang, C.Y.; Chen, K.H.; Wang, Y.H.; Hsueh, P.R. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J. Antimicrob. Chemother., 2021, 76(8), 1962-1968. doi: 10.1093/jac/dkab093 PMID: 33758946
  14. Al-Abdouh, A.; Bizanti, A.; Barbarawi, M.; Jabri, A.; Kumar, A.; Fashanu, O.E.; Khan, S.U.; Zhao, D.; Antar, A.A.R.; Michos, E.D. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Contemp. Clin. Trials, 2021, 101, 106272. doi: 10.1016/j.cct.2021.106272 PMID: 33422642
  15. Ling, C. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS- CoV-2). J. Integr. Med., 2020, 18(2), 87-88. doi: 10.1016/j.joim.2020.02.004 PMID: 32122812
  16. Yi, L.; Li, Z.; Yuan, K.; Qu, X.; Chen, J.; Wang, G.; Zhang, H.; Luo, H.; Zhu, L.; Jiang, P.; Chen, L.; Shen, Y.; Luo, M.; Zuo, G.; Hu, J.; Duan, D.; Nie, Y.; Shi, X.; Wang, W.; Han, Y.; Li, T.; Liu, Y.; Ding, M.; Deng, H.; Xu, X. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J. Virol., 2004, 78(20), 11334-11339. doi: 10.1128/JVI.78.20.11334-11339.2004 PMID: 15452254
  17. Chen, Y.; Guo, J.; Healy, D.; Zhan, S. Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis. Pharmacy Practice, 2007, 5(1), 1-9. doi: 10.4321/S1886-36552007000100001
  18. Shen, K.; Yang, Y.; Wang, T.; Zhao, D.; Jiang, Y.; Jin, R.; Zheng, Y.; Xu, B.; Xie, Z.; Lin, L.; Shang, Y.; Lu, X.; Shu, S.; Bai, Y.; Deng, J.; Lu, M.; Ye, L.; Wang, X.; Wang, Y.; Gao, L. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: Experts' consensus statement. World J. Ped. WJP, 2020. doi: 10.1007/s12519-020-00343-7
  19. Li, T.; Peng, T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res., 2013, 97(1), 1-9. doi: 10.1016/j.antiviral.2012.10.006 PMID: 23153834
  20. Lin, L.T.; Hsu, W.C.; Lin, C.C. Antiviral natural products and herbal medicines. J. Tradit. Complement. Med., 2014, 4(1), 24-35. doi: 10.4103/2225-4110.124335 PMID: 24872930
  21. Leong, P.K.; Wong, H.S.; Chen, J.; Ko, K.M. Yang/Qi invigoration: an herbal therapy for chronic fatigue syndrome with yang deficiency? Evidence-based complementary and alternative medicine: eCAM, 2015, 2015(3), 945901. doi: 10.1155/2015/945901
  22. Zhao, F.; Yang, Z.; Wang, N.; Jin, K.; Luo, Y. Traditional Chinese medicine and Western medicine share similar philosophical approaches to fight COVID-19. Aging Dis., 2021, 12(5), 1162-1168. doi: 10.14336/AD.2021.0512 PMID: 34341699
  23. Luo, H.; Gao, Y.; Zou, J.; Zhang, S.; Chen, H.; Liu, Q.; Tan, D.; Han, Y.; Zhao, Y.; Wang, S. Reflections on treatment of COVID-19 with traditional Chinese medicine. Chin. Med., 2020, 15(1), 94. doi: 10.1186/s13020-020-00375-1 PMID: 32905189
  24. Wu, D.; Hou, X.; Xia, Z.; Hao, E.; Xie, J.; Liang, J.; Liang, Q.; Du, Z.; Deng, J. Analysis on oral medication rules of traditional Chinese medicine prescriptions for prevention of COVID-19. Chin. Herb. Med., 2021, 13(4), 502-517. doi: 10.1016/j.chmed.2021.10.007 PMID: 34659385
  25. Ding, X.; Fan, L.L.; Zhang, S.X.; Ma, X.X.; Meng, P.F.; Li, L.P.; Huang, M.Y.; Guo, J.L.; Zhong, P.Z.; Xu, L.R. Traditional Chinese medicine in treatment of COVID-19 and viral disease: Efficacies and clinical evidence. Int. J. Gen. Med., 2022, 15, 8353-8363. doi: 10.2147/IJGM.S386375 PMID: 36465269
  26. Lyu, M.; Fan, G.; Xiao, G.; Wang, T.; Xu, D.; Gao, J.; Ge, S.; Li, Q.; Ma, Y.; Zhang, H.; Wang, J.; Cui, Y.; Zhang, J.; Zhu, Y.; Zhang, B. Traditional Chinese medicine in COVID-19. Acta Pharm. Sin. B, 2021, 11(11), 3337-3363. doi: 10.1016/j.apsb.2021.09.008 PMID: 34567957
  27. Luo, L.; Jiang, J.; Wang, C.; Fitzgerald, M.; Hu, W.; Zhou, Y.; Zhang, H.; Chen, S. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharm. Sin. B, 2020, 10(7), 1192-1204. doi: 10.1016/j.apsb.2020.05.007 PMID: 32834949
  28. Luo, H.; Tang, Q.; Shang, Y.; Liang, S.; Yang, M.; Robinson, N.; Liu, J. Can chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin. J. Integr. Med., 2020, 26(4), 243-250. doi: 10.1007/s11655-020-3192-6 PMID: 32065348
  29. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet, 2003, 361(9374), 2045-2046. doi: 10.1016/S0140-6736(03)13615-X PMID: 12814717
  30. Leung, E.L.H.; Pan, H.D.; Huang, Y.F.; Fan, X.X.; Wang, W.Y.; He, F.; Cai, J.; Zhou, H.; Liu, L. The scientific foundation of Chinese herbal medicine against COVID-19. Engineering, 2020, 6(10), 1099-1107. doi: 10.1016/j.eng.2020.08.009 PMID: 33520331
  31. Law, S.; Lo, C.; Han, J.; Leung, A.W.; Xu, C. Traditional Chinese herb, Astragalus : Possible for treatment and prevention of COVID-19? Herba Pol., 2020, 66(4), 79-84. doi: 10.2478/hepo-2020-0023
  32. Yu, M.S.; Lee, J.; Lee, J.M.; Kim, Y.; Chin, Y.W.; Jee, J.G.; Keum, Y.S.; Jeong, Y.J. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg. Med. Chem. Lett., 2012, 22(12), 4049-4054. doi: 10.1016/j.bmcl.2012.04.081 PMID: 22578462
  33. Cheng, P.W.; Ng, L.T.; Chiang, L.C.; Lin, C.C. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin. Exp. Pharmacol. Physiol., 2006, 33(7), 612-616. doi: 10.1111/j.1440-1681.2006.04415.x PMID: 16789928
  34. Li, S.; Chen, C.; Zhang, H.; Guo, H.; Wang, H.; Wang, L.; Zhang, X.; Hua, S.; Yu, J.; Xiao, P.; Li, R.S.; Tan, X. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res., 2005, 67(1), 18-23. doi: 10.1016/j.antiviral.2005.02.007 PMID: 15885816
  35. Kim, D.; Min, J.; Jang, M.; Lee, J.; Shin, Y.; Park, C.; Song, J.; Kim, H.; Kim, S.; Jin, Y-H.; Kwon, S. Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules, 2019, 9(11), 696. doi: 10.3390/biom9110696 PMID: 31690059
  36. Lau, K.M.; Lee, K.M.; Koon, C.M.; Cheung, C.S.F.; Lau, C.P.; Ho, H.M.; Lee, M.Y.H.; Au, S.W.N.; Cheng, C.H.K.; Lau, C.B.S.; Tsui, S.K.W.; Wan, D.C.C.; Waye, M.M.Y.; Wong, K.B.; Wong, C.K.; Lam, C.W.K.; Leung, P.C.; Fung, K.P. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J. Ethnopharmacol., 2008, 118(1), 79-85. doi: 10.1016/j.jep.2008.03.018 PMID: 18479853
  37. Lin, C.W.; Tsai, F.J.; Tsai, C.H.; Lai, C.C.; Wan, L.; Ho, T.Y.; Hsieh, C.C.; Chao, P.D.L. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res., 2005, 68(1), 36-42. doi: 10.1016/j.antiviral.2005.07.002 PMID: 16115693
  38. Ryu, Y.B.; Jeong, H.J.; Kim, J.H.; Kim, Y.M.; Park, J.Y.; Kim, D.; Naguyen, T.T.H.; Park, S.J.; Chang, J.S.; Park, K.H.; Rho, M-C.; Lee, W.S. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg. Med. Chem., 2010, 18(22), 7940-7947. doi: 10.1016/j.bmc.2010.09.035 PMID: 20934345
  39. Luo, W.; Su, X.; Gong, S.; Qin, Y.; Liu, W.; Li, J.; Yu, H.; Xu, Q. Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. Biosci. Trends, 2009, 3(4), 124-126. PMID: 20103835
  40. Marshall, A.C. Traditional Chinese medicine and clinical pharmacology; Springer, 2020.
  41. Zhou, X.; Li, C.G.; Chang, D.; Bensoussan, A. Current status and major challenges to the safety and efficacy presented by Chinese herbal medicine. Medicines, 2019, 6(1), 14. doi: 10.3390/medicines6010014 PMID: 30669335
  42. Wei, P-F. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chinese Med. J., 2020, 133(9), 1087-1095. doi: 10.1097/CM9.0000000000001399 PMID: 32358325
  43. Liu, Y.; Liu, W.; Peng, Q.X.; Peng, J.L.; Yu, L.Z.; Hu, J.L. Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic acid. Evidence-based complementary and alternative medicine: eCAM, 2014, 2014, 218383. doi: 10.1155/2014/218383
  44. He, Y.H.; Luo, X.J.; Qian, X.W.; Wu, Z.P.; Lv, A.P. Effects of Huoxiang Zhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea. Zhongguo Zhongyao Zazhi, 2007, 32(22), 2397-2400. PMID: 18257268
  45. Chinese Pharmaceutical Association. 2020 http://english.nmpa.gov.cn/2019-07/19/c_389182.htm
  46. Xiao, M.; Tian, J.; Zhou, Y.; Xu, X.; Min, X.; Lv, Y.; Peng, M.; Zhang, Y.; Yan, D.; Lang, S.; Zhang, Q.; Fan, A.; Ke, J.; Li, X.; Liu, B.; Jiang, M.; Liu, Q.; Zhu, J.; Yang, L.; Zhu, Z.; Zeng, K.; Li, C.; Zheng, Y.; Wu, H.; Lin, J.; Lian, F.; Li, X.; Tong, X. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol. Res., 2020, 161, 105126. doi: 10.1016/j.phrs.2020.105126 PMID: 32781283
  47. Yang, H.; Li, Y.; Cao, L.; Feng, X.; Zhang, J.; Jiang, S.; Su, Z.; Lai, C.; Zhou, D. Huoxiang Zhengqi Powder combined with western medicine in the treatment of 11 COVID-19 cases. Guangxi Trad. Chin. Med., 2020, 43(3), 1-4.
  48. Chen, H.; Song, Y.P.; Gao, K.; Zhao, L.T.; Ma, L. Efficacy and safety of Jinhua Qinggan granules for coronavirus disease 2019 (COVID-19). Medicine, 2020, 99(24), e20612. doi: 10.1097/MD.0000000000020612 PMID: 32541495
  49. Shah, M.R.; Fatima, S.; Khan, S.N.; Shafiullah.; Himani, G.; Wan, K.; Lin, T.; Lau, J.Y.N.; Liu, Q.; Lam, D.S.C. Jinhua qinggan granules for nonhospitalized COVID-19 patients: a double-blind, placebo-controlled, randomized controlled trial. medRxiv, 2022. doi: 10.1101/2022.05.16.22275074
  50. Wang, C.H.; Zhong, Y.; Zhang, Y.; Liu, J.P.; Wang, Y.F.; Jia, W.N.; Wang, G.C.; Li, Z.; Zhu, Y.; Gao, X.M. WHO. SARS : Clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine. Geneva: World Health Organization; 2004. Mol. Biosyst., 2016, 12(2), 606-613. doi: 10.1039/C5MB00448A PMID: 26687282
  51. Jia, W.; Wang, C.; Wang, Y.; Pan, G.; Jiang, M.; Li, Z.; Zhu, Y. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. ScientificWorldJournal, 2015, 2015, 1-19. doi: 10.1155/2015/731765 PMID: 25654135
  52. Dong, Z.; Lu, X.; Tong, X.; Dong, Y.; Tang, L.; Liu, M. Forsythiae Fructus: A review on its phytochemistry, quality control, pharmacology and pharmacokinetics. Molecules, 2017, 22(9), 1466. doi: 10.3390/molecules22091466 PMID: 28869577
  53. Xiong, X.; Wang, P.; Su, K.; Cho, W.C.; Xing, Y. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol. Res., 2020, 160, 105056. doi: 10.1016/j.phrs.2020.105056 PMID: 32622723
  54. Niu, Q.Q.; Chen, Y.; Liu, Y.; Mao, S.Z.; Wang, H.; Zheng, W.K.; Zhang, J.H. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. Zhongguo Zhongyao Zazhi, 2017, 42(8), 1474-1481. doi: 10.19540/j.cnki.cjcmm.2017.0044 PMID: 29071849
  55. Runfeng, L.; Yunlong, H.; Jicheng, H.; Weiqi, P.; Qinhai, M.; Yongxia, S.; Chufang, L.; Jin, Z.; Zhenhua, J.; Haiming, J.; Kui, Z.; Shuxiang, H.; Jun, D.; Xiaobo, L.; Xiaotao, H.; Lin, W.; Nanshan, Z.; Zifeng, Y. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol. Res., 2020, 156, 104761. doi: 10.1016/j.phrs.2020.104761 PMID: 32205232
  56. Bao, Y.; Gao, Y.; Cui, X. Effect of Shufeng Jiedu capsules as a broad-spectrum antibacterial. Biosci. Trends, 2016, 10(1), 74-78. doi: 10.5582/bst.2015.01172 PMID: 26875500
  57. Tao, Z.; Gao, J.; Zhang, G.; Xue, M.; Yang, W.; Tong, C.; Yuan, Y. Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-κB pathway. Biosci. Trends, 2014, 8(1), 45-51. doi: 10.5582/bst.8.45 PMID: 24647112
  58. Yuan, Y.; Liao, Q.; Xue, M.; Shi, Y.; Rong, L.; Song, Z.; Tong, Z.; Zheng, W.; Zhu, Q.; Cui, X.; Tao, Z. Capsules alleviate lipopolysaccharide-induced acute lung inflammatory injury via activation of GPR18 by verbenalin. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, 50(2), 629-639. doi: 10.1159/000494184
  59. Xi, Z.; Zhou, J.; Mei, J.T; Ge, A.; Zheng, Y. Effect of Shufeng Jiedu capsule on the fever caused by viral upper respiratory tract infection: A report of 130 cases. J. Tradit. Chin. Med., 2010, 51, 426-427.
  60. Xia, J.; Rong, L.; Sawakami, T.; Inagaki, Y.; Song, P.; Hasegawa, K.; Sakamoto, Y.; Tang, W. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma. Biomed. Pharmacother., 2018, 99, 921-930. doi: 10.1016/j.biopha.2018.01.163 PMID: 29710492
  61. Chen, S.; Kwong, J.S.W.; Zheng, R.; Wang, Y.; Shang, H. Normative application of xiyanping injection: A systematic review of adverse case reports. Evid. Based Complement. Alternat. Med., 2018, 2018, 1-14. doi: 10.1155/2018/4013912 PMID: 30581483
  62. Shi, H.; Guo, W.; Zhu, H.; Li, M.; Ung, C.O.L.; Hu, H.; Han, S. Cost-effectiveness analysis of Xiyanping injection (Andrographolide Sulfonate) for treatment of adult community acquired pneumonia: A retrospective, propensity score-matched cohort study. Evid. Based Complement. Alternat. Med., 2019, 2019, 4510591. doi: 10.1155/2019/4510591
  63. Song, Y.; Yao, C.; Shang, H.; Yao, X.; Bai, C. Intravenous infusion of Chinese medicine Xuebijing for patients with severe pneumonia: A multicenter, randomised, double-blind controlled trial. Lancet, 2017, 390, S34. doi: 10.1016/S0140-6736(17)33172-0
  64. Sun, Z.; Zuo, L.; Sun, T.; Tang, J.; Ding, D.; Zhou, L.; Kang, J.; Zhang, X. Chemical profiling and quantification of XueBiJing injection, a systematic quality control strategy using UHPLC-Q Exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry. Sci. Rep., 2017, 7(1), 16921. doi: 10.1038/s41598-017-17170-y PMID: 29208914
  65. Song, Y.; Yao, C.; Yao, Y.; Han, H.; Zhao, X.; Yu, K.; Liu, L.; Xu, Y.; Liu, Z.; Zhou, Q.; Wang, Y.; Ma, Z.; Zheng, Y.; Wu, D.; Tang, Z.; Zhang, M.; Pan, S.; Chai, Y.; Song, Y.; Zhang, J.; Pan, L.; Liu, Y.; Yu, H.; Yu, X.; Zhang, H.; Wang, X.; Du, Z.; Wan, X.; Tang, Y.; Tian, Y.; Zhu, Y.; Wang, H.; Yan, X.; Liu, Z.; Zhang, B.; Zhong, N.; Shang, H.; Bai, C. XueBiJing injection versus placebo for critically Ill patients with severe community-acquired pneumonia. Crit. Care Med., 2019, 47(9), e735-e743. doi: 10.1097/CCM.0000000000003842 PMID: 31162191
  66. Qi, F.; Liang, Z.; She, D.; Yan, G.T.; Chen, L. A clinical study on the effects and mechanism of Xuebijing injection in severe pneumonia patients. J. Tradit. Chin. Med., 2011, 31(1), 46-49. doi: 10.1016/S0254-6272(11)60011-3 PMID: 21563507
  67. Li, H.; Yu, Y.; Wang, Z.; Geng, J.; Dai, Y.; Xiao, W.; Yao, X. Chemical profiling of Re-Du-Ning injection by ultra-performance liquid chromatography coupled with electrospray ionization tandem quadrupole time-of-flight mass spectrometry through the screening of diagnostic Ions in MS(E) mode. PLoS One, 2015, 10(4), e0121031. doi: 10.1371/journal.pone.0121031 PMID: 25875968
  68. Liu, Y.; Mu, W.; Xiao, W.; Wei, B.L.; Wang, L.; Liu, X.Q.; Xiong, X.D.; Huang, X.M.; Zhang, Y.Q.; Chen, H.M.; Yan, F.J.; Tan, Y.P.; Huang, Y.H. Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial. Oncotarget, 2017, 8(33), 55176-55186. doi: 10.18632/oncotarget.19220 PMID: 28903411
  69. Wang, F.; Li, C.; Zheng, Y.; Li, H.; Xiao, W.; Peng, G. Identification of the allergenic ingredients in reduning injection by ultrafiltration and high-performance liquid chromatography. J. Immunol. Res., 2016, 2016, 1-7. doi: 10.1155/2016/4895672 PMID: 27144180
  70. Wang, P.; Liao, X.; Xie, Y.M.; Chai, Y.; Li, L.H. Tanreqing injection for acute bronchitis disease: A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med., 2016, 25, 143-158. doi: 10.1016/j.ctim.2016.02.008 PMID: 27062962
  71. Liu, W.; Jiang, H.; Cai, L.; Yan, M.; Dong, S.; Mao, B. Tanreqing injection attenuates lipopolysaccharide-induced airway inflammation through MAPK/NF- κ B signaling pathways in rats model. Evid. Based Complement. Alternat. Med., 2016, 2016, 1-15. doi: 10.1155/2016/5292346 PMID: 27366191
  72. Zhang, Y.M.; Qu, X.Y.; Zhai, J.H.; Tao, L.N.; Gao, H.; Song, Y.Q.; Zhang, S.X. Xingnaojing injection protects against cerebral ischemia reperfusion injury via PI3K/Akt-Mediated eNOS Phosphorylation. Evid. Based Complement. Alternat. Med., 2018, 2018, 1-13. doi: 10.1155/2018/2361046 PMID: 30158991
  73. Wu, L.; Zhang, H.; Xing, Y.; Gao, Y.; Li, Y.; Ren, X.; Li, J.; Nie, B.; Zhu, L.; Shang, H.; Gao, Y. Meta-analysis of the effects of Xingnaojing injection on consciousness disturbance. Medicine, 2016, 95(7), e2875. doi: 10.1097/MD.0000000000002875 PMID: 26886655
  74. Madjid, M.; Safavi-Naeini, P.; Solomon, S.D.; Vardeny, O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol., 2020, 5(7), 831-840. doi: 10.1001/jamacardio.2020.1286 PMID: 32219363
  75. WHO. SARS : clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine. Geneva: World Health Organization; 2004.
  76. Mou, Z.; Lv, Z.; Li, Y.; Wang, M.; Xu, Q.; Yu, X. Clinical effect of shenfu injection in patients with septic shock: a meta-analysis and systematic review. Evid. Based Complement. Alternat. Med., 2015, 2015, 863149. doi: 10.1155/2015/863149
  77. Li, Y.; Zhang, X.; Lin, P.; Qiu, H.; Wei, J.; Cao, Y.; Pan, S.; Walline, J.; Qian, C.; Shan, Z.; Yu, X. Effects of Shenfu injection in the treatment of septic shock patients: A multicenter, controlled, randomized, open-label trial. Evid. Based Complement. Alternat. Med., 2016, 2016, 2565169. doi: 10.1155/2016/2565169
  78. Leong, P.K.; Ko, K.M.; San, S. Shengmai San: a modern medicine perspective on its remedial effects on Qi and Yin deficiency syndrome in Chinese medicine. Longhua Chin. Med., 2018, 1, 13-13. doi: 10.21037/lcm.2018.09.03
  79. Zhou, Q.; Qin, W.Z.; Liu, S.B.; Kwong, J.S.W.; Zhou, J.; Chen, J. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst. Rev., 2014, (4), CD005052. doi: 10.1002/14651858.CD005052.pub5 PMID: 24733159
  80. Wang, C.; Sun, S.; Ding, X. The therapeutic effects of traditional chinese medicine on COVID-19: A narrative review. Int. J. Clin. Pharm., 2021, 43(1), 35-45. doi: 10.1007/s11096-020-01153-7 PMID: 32974857
  81. Lu, L.-Y.; Zheng, g.-q.; Wang, Y. An overview of systematic reviews of shenmai injection for healthcare. Evi. Compl. Altern Med.: eCAM, 2014, 2014, 840650. doi: 10.1155/2014/840650
  82. Shi, L.; Xie, Y.; Liao, X.; Chai, Y.; Luo, Y. Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: A systematic review and meta-analysis of randomized controlled trials. BMC Complement. Altern. Med., 2015, 15(1), 418. doi: 10.1186/s12906-015-0939-2 PMID: 26603978
  83. Zhu, X.B.; Guo, M.; Zhang, Z.H.; Sun, L.H.; Liu, L.; Zhou, L.J.; Shan, C.L.; Yang, Y.; Kan, L.D.; Li, L.C. Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review. Integr. Med. Res., 2021, 10(4), 100778. doi: 10.1016/j.imr.2021.100778 PMID: 34608432
  84. Pharmacopoeia of The People's Republic of China, 1st ed.; People's Medical Publishing House: Ovid, 2005.
  85. Luo, H.; Yang, M.; Tang, Q.L.; Hu, X.Y.; Willcox, M.L.; Liu, J.P. Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review. Eur. J. Integr. Med., 2021, 41, 101251. doi: 10.1016/j.eujim.2020.101251 PMID: 33204368
  86. Li, G.Q.; Zhao, J.; Tu, Z.T.; Li, J.B.; Liu, Q.Q.; Shi, L.Q.; Miao, Q.; Yuan, H.Q.; Liu, X.Q.; Long, Y.Y.; Liu, Z.G.; Zhao, T.; Li, L.; Tant, Q.H.; He, Y.C.; Bian, Y.J.; Hu, J.Q. Treating influenza patients of wind-heat affecting Fei syndrome by Jinhua Qinggan granule: a double-blinded randomized control trial. Chin. J. Integrat. Trad. Western Med., 2013, 33(12), 1631-1635.
  87. Use of Patented Traditional Chinese Medicine against COVID-19; WORLD SCIENTIFIC, 2020. doi: 10.1142/12029

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers